Equibles does not estimate personal net worth.
Get an email with a short summary when Tarsus Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get TARS alertsJeffrey S. Farrow is recorded as CFO at Tarsus Pharmaceuticals, Inc. (TARS). The newest filing on record that lists Jeffrey S. Farrow as CFO at Tarsus Pharmaceuticals, Inc. (TARS) is dated April 28, 2026. The proxy statement of Tarsus Pharmaceuticals, Inc. reports total compensation of $2,677,617 for Jeffrey S. Farrow in fiscal 2025, including a base salary of $541,667. Disclosed compensation is on record for 3 fiscal years. Jeffrey S. Farrow has spoken on 1 earnings call across 1 company, most recently for Tarsus Pharmaceuticals, Inc. on May 8, 2024. Tarsus Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tarsus Pharmaceuticals, Inc. includes Bobak Azamian (CEO and Chairman), Leonard Greenstein (CFO), Seshadri Neervannan (COO) and 7 others.
“The first quarter of 2024 was another example of how we are continuing to raise the bar for eye care product launches.”
Start not stated–present
Last confirmed April 28, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Tarsus Pharmaceuticals, Inc. (TARS) | Chief Financial Officer and Chief Strategy Officer | $541,667 | $2,677,617 |
| 2024 | Tarsus Pharmaceuticals, Inc. (TARS) | Chief Financial Officer and Chief Strategy Officer | $520,833 | $3,232,926 |
| 2023 | Tarsus Pharmaceuticals, Inc. (TARS) | Chief Financial Officer and Chief Strategy Officer | $343,751 | $3,991,830 |
